Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering
April 22 2021 - 6:48PM
Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical
company focused on utilizing its proprietary technology to develop
and commercialize transformative therapies for patients suffering
from diseases with high unmet medical needs, today announced
the pricing of its initial public offering of 5,333,334 shares of
its common stock at a price to the public of $15.00 per share. All
of the shares are being offered by Impel. The shares are expected
to begin trading on The Nasdaq Global Market on April 23, 2021
under the symbol “IMPL.” The gross proceeds from the offering,
before deducting underwriting discounts and commissions and other
offering expenses payable by Impel, are expected to be $80.0
million. In addition, Impel has granted the underwriters a 30-day
option to purchase up to an additional 800,000 shares of common
stock at the initial public offering price, less underwriting
discounts and commissions. The offering is expected to close on
April 27, 2021, subject to the satisfaction of customary closing
conditions.
Cowen and Guggenheim Securities are acting as joint bookrunning
managers for the proposed offering. Wedbush PacGrow is acting as
lead manager.
A registration statement relating to these
securities has been filed with the Securities and Exchange
Commission and became effective on April 22, 2021. The offering is
being made only by means of a prospectus. A copy of the final
prospectus relating to the offering, when available, may be
obtained from: Cowen and Company, LLC, c/o Broadridge Financial
Solutions, Attn: Prospectus Department, 1155 Long Island Avenue,
Edgewood, NY 11717, or by telephone at (833) 297-2926 or by email
at PostSaleManualRequests@broadridge.com; or Guggenheim
Securities, LLC Attention: Equity Syndicate Department, 330 Madison
Avenue, New York, NY 10017 or by telephone at (212) 518-9544, or by
email
at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Impel NeuroPharma:
Impel NeuroPharma, Inc. is a late-stage
pharmaceutical company focused on utilizing its proprietary
technology to develop and commercialize transformative therapies
for people suffering from diseases with high unmet needs, with an
initial focus on diseases of the CNS. The Company’s strategy is to
rapidly advance its product candidate pipeline that pairs its
proprietary Precision Olfactory Delivery (POD®) system with
well-established therapeutics, including TRUDHESA™ for the acute
treatment of migraine, INP105 for the acute treatment of agitation
and aggression in patients with autism, and INP107 for OFF episodes
in Parkinson’s disease.
Contact
Investor Relations:Christina TartagliaStern
Investor RelationsPhone: (1)
212-362-1200Email: christina.tartaglia@sternir.com
Media Relations:Melyssa WeibleElixir Health
Public RelationsPhone: (1)
201-723-5805Email: mweible@elixirhealthpr.com
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Jul 2023 to Jul 2024